See more : JSW Infrastructure Limited (JSWINFRA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Xianju Pharmaceutical Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Stemcell United Limited (SCU.AX) Income Statement Analysis – Financial Results
- Eurocash S.A. (EUR.WA) Income Statement Analysis – Financial Results
- All About, Inc. (2454.T) Income Statement Analysis – Financial Results
- Jilin Expressway Co., Ltd. (601518.SS) Income Statement Analysis – Financial Results
- Musashi Co., Ltd. (7521.T) Income Statement Analysis – Financial Results
Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.xjpharma.com
About Zhejiang Xianju Pharmaceutical Co.,Ltd.
Zhejiang Xianju Pharmaceutical Co.,Ltd. manufactures and sells steroids and hormones worldwide. The company offers active pharmaceutical ingredients, such as steroid drugs, and male and female hormones; intermediates; and finished formulations in the form of tablets, capsules, granules, soft capsules, powder inhalations, creams, gels, injections, and powder-injections. Zhejiang Xianju Pharmaceutical Co.,Ltd. was founded in 1972 and is based in Xianju, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.12B | 4.38B | 4.34B | 4.02B | 3.71B | 3.62B | 2.85B | 2.50B | 2.48B | 2.47B | 2.32B | 1.99B | 1.69B | 1.50B | 1.28B | 1.13B | 966.79M | 765.33M |
| Cost of Revenue | 1.97B | 1.83B | 1.81B | 1.78B | 1.46B | 1.48B | 1.25B | 1.23B | 1.40B | 1.52B | 1.52B | 1.20B | 1.01B | 926.48M | 742.83M | 696.53M | 594.76M | 492.50M |
| Gross Profit | 2.15B | 2.55B | 2.53B | 2.24B | 2.25B | 2.14B | 1.61B | 1.28B | 1.08B | 955.26M | 797.53M | 790.33M | 679.42M | 574.50M | 533.89M | 436.98M | 372.02M | 272.83M |
| Gross Profit Ratio | 52.18% | 58.15% | 58.23% | 55.64% | 60.54% | 59.09% | 56.32% | 50.93% | 43.72% | 38.67% | 34.45% | 39.67% | 40.22% | 38.27% | 41.82% | 38.55% | 38.48% | 35.65% |
| Research & Development | 266.97M | 266.77M | 243.37M | 208.39M | 204.52M | 142.85M | 88.15M | 87.14M | 86.50M | 88.41M | 79.67M | 60.03M | 49.19M | 48.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 122.08M | 95.28M | 104.30M | 81.79M | 98.99M | 96.57M | 76.84M | 74.91M | 66.28M | 65.18M | 55.82M | 51.48M | 49.05M | 36.65M | 141.28M | 111.64M | 101.78M | 70.36M |
| Selling & Marketing | 802.69M | 1.26B | 1.28B | 1.10B | 1.13B | 1.19B | 938.97M | 775.76M | 619.58M | 550.98M | 435.53M | 391.88M | 325.15M | 259.11M | 230.22M | 186.18M | 154.67M | 114.29M |
| SG&A | 1.23B | 1.36B | 1.38B | 1.18B | 1.23B | 1.29B | 1.02B | 850.66M | 685.86M | 616.16M | 491.35M | 443.36M | 374.19M | 295.76M | 371.50M | 297.82M | 256.45M | 184.65M |
| Other Expenses | 0.00 | 169.86M | 178.30M | 165.01M | 182.79M | -862.38K | -5.99M | 7.04M | 12.02M | 4.71M | 2.21M | -826.52K | 5.39M | 23.72K | 4.00M | 3.64M | 187.75K | 516.45K |
| Operating Expenses | 1.53B | 1.79B | 1.81B | 1.55B | 1.61B | 1.61B | 1.23B | 1.07B | 903.24M | 817.07M | 671.76M | 590.77M | 497.31M | 408.72M | 379.83M | 304.58M | 262.61M | 188.65M |
| Cost & Expenses | 3.48B | 3.63B | 3.62B | 3.33B | 3.08B | 3.09B | 2.47B | 2.30B | 2.30B | 2.33B | 2.19B | 1.79B | 1.51B | 1.34B | 1.12B | 1.00B | 857.37M | 681.15M |
| Interest Income | 38.28M | 27.19M | 14.61M | 8.84M | 8.92M | 4.81M | 6.22M | 2.01M | 1.70M | 2.56M | 3.53M | 7.72M | 14.53M | 4.45M | 0.00 | -0.17 | -0.79 | -0.19 |
| Interest Expense | 6.64M | 6.29M | 23.10M | 49.23M | 59.84M | 66.39M | 44.69M | 38.42M | 63.17M | 63.23M | 54.21M | 43.06M | 29.17M | 26.41M | 35.60M | 46.31M | 33.51M | 27.10M |
| Depreciation & Amortization | 218.91M | 195.74M | 193.84M | 180.30M | 149.98M | 131.97M | 98.67M | 95.61M | 91.16M | 84.19M | 61.27M | 41.60M | 36.38M | 32.19M | 32.94M | 33.84M | 30.26M | 31.09M |
| EBITDA | 863.96M | 1.02B | 946.88M | 865.85M | 744.44M | 645.82M | 432.73M | 313.69M | 282.23M | 220.60M | 185.57M | 238.61M | 232.82M | 190.23M | 186.99M | 166.24M | 137.76M | 115.27M |
| EBITDA Ratio | 20.95% | 23.31% | 21.50% | 21.30% | 20.52% | 18.14% | 16.14% | 13.16% | 12.36% | 9.53% | 8.57% | 12.85% | 14.49% | 14.34% | 15.78% | 15.69% | 14.25% | 16.26% |
| Operating Income | 646.46M | 878.60M | 754.67M | 597.24M | 543.40M | 431.25M | 297.64M | 178.06M | 116.24M | 69.11M | 70.20M | 160.25M | 163.56M | 148.51M | 113.31M | 80.21M | 94.93M | 71.08M |
| Operating Income Ratio | 15.68% | 20.06% | 17.40% | 14.86% | 14.65% | 11.91% | 10.43% | 7.11% | 4.69% | 2.80% | 3.03% | 8.04% | 9.68% | 9.89% | 8.88% | 7.08% | 9.82% | 9.29% |
| Total Other Income/Expenses | -4.78M | -2.83M | -24.81M | 24.01M | -16.10M | -862.38K | -43.88M | 4.97M | -31.06M | -60.60M | -45.10M | -33.79M | 3.72M | -815.54K | -32.74M | -49.28M | -1.22M | 159.37K |
| Income Before Tax | 641.68M | 871.89M | 725.89M | 621.25M | 527.30M | 430.38M | 291.65M | 183.03M | 127.90M | 73.18M | 70.09M | 153.95M | 167.28M | 147.69M | 116.00M | 83.11M | 93.71M | 71.24M |
| Income Before Tax Ratio | 15.56% | 19.91% | 16.74% | 15.46% | 14.22% | 11.88% | 10.22% | 7.31% | 5.16% | 2.96% | 3.03% | 7.73% | 9.90% | 9.84% | 9.09% | 7.33% | 9.69% | 9.31% |
| Income Tax Expense | 79.56M | 124.51M | 108.01M | 92.25M | 84.82M | 85.01M | 61.55M | 36.62M | 23.30M | 24.36M | 19.48M | 29.72M | 35.24M | 33.08M | 31.37M | 20.99M | 32.36M | 20.88M |
| Net Income | 563.08M | 749.41M | 619.33M | 504.51M | 410.37M | 301.36M | 206.63M | 146.19M | 106.55M | 56.70M | 60.59M | 120.56M | 132.87M | 120.17M | 88.84M | 65.04M | 64.64M | 49.53M |
| Net Income Ratio | 13.66% | 17.11% | 14.28% | 12.55% | 11.07% | 8.32% | 7.24% | 5.84% | 4.30% | 2.29% | 2.62% | 6.05% | 7.87% | 8.01% | 6.96% | 5.74% | 6.69% | 6.47% |
| EPS | 0.57 | 0.76 | 0.63 | 0.51 | 0.45 | 0.33 | 0.23 | 0.16 | 0.13 | 0.07 | 0.08 | 0.16 | 0.17 | 0.16 | 0.16 | 0.11 | 0.11 | 0.08 |
| EPS Diluted | 0.57 | 0.76 | 0.63 | 0.51 | 0.45 | 0.33 | 0.23 | 0.16 | 0.13 | 0.07 | 0.08 | 0.16 | 0.17 | 0.16 | 0.16 | 0.11 | 0.11 | 0.08 |
| Weighted Avg Shares Out | 987.87M | 989.20M | 989.20M | 989.20M | 916.21M | 913.22M | 898.39M | 913.67M | 799.13M | 773.12M | 757.39M | 774.79M | 766.56M | 772.49M | 571.13M | 585.34M | 581.73M | 586.54M |
| Weighted Avg Shares Out (Dil) | 987.87M | 989.20M | 989.20M | 989.20M | 916.21M | 913.22M | 898.39M | 913.67M | 799.13M | 773.12M | 757.39M | 775.01M | 766.56M | 772.49M | 571.13M | 585.34M | 581.73M | 586.54M |
Source: https://incomestatements.info
Category: Stock Reports